Karen Akinsanya - 15 Sep 2021 Form 4 Insider Report for Schrodinger, Inc. (SDGR)

Role
EVP, Chief Biomedical Scientist, Head of Discovery R&D
Signature
/s/ Donald Shum, as attorney-in-fact for Karen Akinsanya
Issuer symbol
SDGR
Transactions as of
15 Sep 2021
Net transactions value
-$79,165
Form type
4
Filing time
16 Sep 2021, 17:01:14 UTC
Previous filing
17 Aug 2021
Next filing
19 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SDGR Common Stock Options Exercise $6,050 +1,394 $4.34* 1,394 15 Sep 2021 Direct F1
transaction SDGR Common Stock Sale $85,215 -1,394 -100% $61.13 0 15 Sep 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SDGR Stock Option (right to buy) Options Exercise $0 -1,394 -3% $0.000000 44,591 15 Sep 2021 Common Stock 1,394 $4.34 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021.
F2 This option was granted on November 29, 2018. The shares underlying the option vested with respect to 25% of the shares on December 31, 2019 and the remainder are scheduled to vest in equal monthly installments through December 31, 2022.

Remarks:

EVP, Chief Biomedical Scientist, Head of Discovery R&D